

[← News](#)

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 September-3 October 2024

4 October 2024

Review of medicines containing finasteride and
dutasteride started

[News](#)[Human](#)[Medicines](#)[Pharmacovigilance](#)[Referrals](#)[Share](#)

Review of medicines containing finasteride and dutasteride started

Review assesses data related to suicidal thoughts and behaviours

EMA has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviours.

Tablets containing 1 mg finasteride and finasteride solution for application to the skin are used to treat the early stages of androgenic alopecia (hair loss due to male hormones) in men aged 18 to 41 years. Tablets containing 5 mg finasteride and capsules containing 0.5 mg dutasteride are used to treat men with benign prostatic hyperplasia (BPH), a condition in which the prostate is enlarged and can cause

problems with the flow of urine.

Medicines containing finasteride and dutasteride taken by mouth have a known risk of psychiatric side effects, including depression. Suicidal ideation has also recently been added as a possible side effect of unknown frequency in the product information for Propecia and Proscar, the first two finasteride-containing medicines authorised in several countries of the European Union (EU).

To minimise the risks, measures are already in place for finasteride medicines, including warnings in the product information for healthcare professionals to monitor patients for psychiatric symptoms, stop treatment if symptoms occur, and recommendations for patients to seek medical advice if they experience psychiatric symptoms.

More information is available in EMA's [public health communication](#).

New safety information for healthcare professionals: risk of medication errors due to change of dosing syringe for Keppra and Levetiracetam UCB oral solution

Keppra and Levetiracetam UCB are medicines used to treat epilepsy, on their own or as an add-on to another anti-epileptic medicine.

The PRAC discussed a direct healthcare professional communication (DHPC) regarding a change to the dosing syringe included in the product packaging of Keppra and Levetiracetam UCB 100 mg/ml oral solution intended for use in children aged 6 months to 4 years (150 ml bottle). The 3 ml dosing syringe is being replaced with a 5 ml dosing syringe. The DHPC will inform healthcare professionals of the potential risk of medication errors due to the change in the volume of the dosing syringe.

When prescribing and dispensing levetiracetam (Keppra and Levetiracetam UCB) oral solution with the new 5 ml syringe, healthcare professionals should inform caregivers about the change in the volume of the dosing syringe. Caregivers

should be informed that while the new 5 ml syringe is graduated every 0.1 ml, it has additional graduations of 0.25 ml compared to the 3 ml syringe. Caregivers should be counselled on the correct dose and how to measure it with the 5 ml syringe. Caregivers should be advised to read the instructions in the package information leaflet on how to recognise signs and symptoms of a levetiracetam overdose and what to do in this situation.

The DHPC for Keppra and Levetiracetam UCB will be forwarded to EMA's human medicines committee (CHMP). When adopted, the DHPC will be disseminated to healthcare professionals by the [marketing authorisation holders](#), according to an agreed communication plan, and published on the [Direct healthcare professional communications](#) page and in [national registers](#) in EU Member States.

Agenda



Agenda of the PRAC meeting 30 September - 03 October 2024

Draft


Reference Number: EMA/PRAC/410474/2024

English (EN) (559.67 KB - PDF)

First published: 30/09/2024

[View](#) 

PRAC statistics: October 2024



PRAC statistics: October 2024

English (EN) (43.82 MB - PDF)

First published: 04/10/2024

[View](#)

Glossary

- **Safety signal assessments.** A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine and an adverse event that warrants further investigation. Safety signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. More information can be found under '[Signal management](#)'.
- **Periodic safety update reports,** abbreviated as PSURs, are reports prepared by the marketing authorisation holder to describe the worldwide safety experience with a medicine in a defined period after its authorisation. PSURs for medicinal products that contain the same active substance or the same combination of active substances but have different marketing authorisations and are authorised in different EU Member States, are jointly assessed in a single assessment procedure. More information can be found under '[Periodic safety update reports: questions and answers](#)'.
- **Risk management plans,** abbreviated as RMPs, are detailed descriptions of the activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicines. Companies are required to submit an RMP to EMA when applying for a marketing authorisation. RMPs are continually updated throughout the lifetime of the medicine as new information becomes available. More information is available under '[Risk-management plans](#)'.
- **Post-authorisation safety studies,** abbreviated as PASSs, are studies carried out after a medicine has been authorised to obtain further information on its safety, or to measure the effectiveness of risk-management measures. The PRAC assesses the protocols (aspects related to the organisation of a study) and the results of PASSs. More information can be found under '[Post-authorisation safety studies](#)'.
- **Referrals** are procedures used to resolve issues such as concerns over the safety or benefit-risk balance of a

medicine or a class of medicines. In a [referral](#) related to safety of medicines, the [PRAC](#) is requested by a Member State or the European Commission to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. More information can be found under [referral procedures](#).

Related content

[Pharmacovigilance Risk Assessment Committee \(PRAC\): 30 September - 3 October 2024](#)

[Pharmacovigilance Risk Assessment Committee \(PRAC\)](#)

Related documents



Abbreviations used in EMA scientific committees and CMD documents, and in relation to EMA's regulatory activities

Reference Number: EMA/899164/2022

English (EN) (403.34 KB - PDF)

First published: 05/10/2012

Last updated: 12/12/2023

[View](#) 

Contact point

Media enquiries

Tel. +31 (0)88 781 8427

E-mail: press@ema.europa.eu

All other enquiries

please submit your request via the [online form](#)

Follow us on X [@EMA_News](#)

Related content

- [Finasteride- and dutasteride-containing medicinal products](#)

Topics

[Medicines](#)

[Pharmacovigilance](#)

[Referrals](#)

Share this page



E-mail



LinkedIn



X



Facebook



[More share options](#)

**Product emergency hotline
OUTSIDE WORKING HOURS**

[About us](#)

[What we do](#)

[Careers](#)

[Committees & working parties](#)

[Regulatory network](#)

[European experts](#)

[Languages](#)

[Frequently asked questions](#)

[Glossaries](#)

[About this website](#)

[Privacy](#)

[Cookies](#)

[Search tips](#)

[Access to documents](#)

[Contacts](#)

[Send a question](#)

[EMA Service Desk \(system support\)](#)

[Services and databases](#)

[European Medicines Agency](#)

[Domenico Scarlattilaan 6](#)

[1083 HS Amsterdam](#)

[The Netherlands](#)

[Tel: +31 \(0\)88 781 6000](#)

[How to find us](#)

[Postal address and deliveries](#)

[Business hours and holidays](#)

[RSS Feed](#)

[X](#)

[YouTube](#)

[LinkedIn](#)

© 1995 - 2024 European Medicines Agency

European Union agencies network

An agency of the European Union